These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39019657)

  • 1. Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.
    Steenackers K; Hanning N; Bruckers L; Desombere I; Marchant A; Ariën KK; Georges D; Soentjens P; D'Onofrio V; Hites M; Berens-Riha N; De Coster I; Damme PV
    Vaccine; 2024 Nov; 42(25):126117. PubMed ID: 39019657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-Up and Comparative Assessment of SARS-CoV-2 IgA, IgG, Neutralizing, and Total Antibody Responses After BNT162b2 or mRNA-1273 Heterologous Booster Vaccination.
    Younes S; Nicolai E; Pieri M; Bernardini S; Daas HI; Al-Sadeq DW; Younes N; Shurrab FM; Nizamuddin PB; Humaira F; Al-Dewik N; Yassine HM; Abu-Raddad LJ; Ismail A; Nasrallah GK
    Influenza Other Respir Viruses; 2024 May; 18(5):e13290. PubMed ID: 38706402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First SARS-CoV-2 Omicron infection as an effective immune booster among mRNA vaccinated individuals: final results from the first phase of the PRIBIVAC randomised clinical trial.
    Poh XY; Lee IR; Tan CW; Chavatte JM; Fong SW; Goh YS; Rouers A; Wong N; Torres-Ruesta A; Mah SYY; Yeoh AYY; Gandhi M; Rahman N; Chin YQ; Lim JJ; Yoong TJK; Rao S; Chia PY; Ong SWX; Lee TH; Sadarangani SP; Lin RJH; Lim DRX; Chia W; Renia L; Ren EC; Lin RTP; Lye DC; Wang LF; Ng LFP; Young BE
    EBioMedicine; 2024 Sep; 107():105275. PubMed ID: 39137572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of Two Doses of BNT162b2 mRNA COVID-19 Vaccine with a ChAdOx1-S Booster Dose among Navy Personnel in Mexico.
    Ventura-Enríquez Y; Cortina-De la Rosa E; Díaz-Padilla E; Murrieta S; Segundo-Martínez S; Fernández-Sánchez V; Vargas-De-León C
    Viruses; 2024 Apr; 16(4):. PubMed ID: 38675894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
    Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
    Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of COVID-19 booster vaccination: A population-based clinical trial to identify the best vaccination strategy.
    Sieghart D; Hana CA; Dürrschmid C; Heinz LX; Haslacher H; Zlesak M; Piccini G; Manenti A; Montomoli E; Jorda A; Fedrizzi C; Hasenoehrl T; Zdravkovic A; Anderle K; Wiedermann U; Drapalik S; Steinbrecher H; Bergmann F; Firbas C; Jordakieva G; Wagner B; Leonardi M; Pierleoni G; Ballini M; Benincasa L; Marchi S; Trombetta C; Perkmann T; Crevenna R; Zeitlinger M; Bonelli M; Aletaha D; Radner H
    J Clin Virol; 2024 Aug; 173():105661. PubMed ID: 38503118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
    Stuart ASV; Shaw RH; Liu X; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Darton T; Dinesh T; Duncan CJA; England A; Faust SN; Ferreira DM; Finn A; Goodman AL; Green CA; Hallis B; Heath PT; Hill H; Horsington BM; Lambe T; Lazarus R; Libri V; Lillie PJ; Mujadidi YF; Payne R; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Screaton GR; Singh N; Turner DPJ; Turner PJ; Vichos I; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2022 Jan; 399(10319):36-49. PubMed ID: 34883053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial.
    Liu X; Shaw RH; Stuart ASV; Greenland M; Aley PK; Andrews NJ; Cameron JC; Charlton S; Clutterbuck EA; Collins AM; Dinesh T; England A; Faust SN; Ferreira DM; Finn A; Green CA; Hallis B; Heath PT; Hill H; Lambe T; Lazarus R; Libri V; Long F; Mujadidi YF; Plested EL; Provstgaard-Morys S; Ramasamy MN; Ramsay M; Read RC; Robinson H; Singh N; Turner DPJ; Turner PJ; Walker LL; White R; Nguyen-Van-Tam JS; Snape MD;
    Lancet; 2021 Sep; 398(10303):856-869. PubMed ID: 34370971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2.
    Markewitz R; Juhl D; Pauli D; Görg S; Junker R; Rupp J; Engel S; Steinhagen K; Herbst V; Zapf D; Krüger C; Brockmann C; Leypoldt F; Dargvainiene J; Schomburg B; Sharifzadeh S; Nejad LS; Wandinger KP; Ziemann M
    Front Immunol; 2022; 13():811020. PubMed ID: 35126395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial.
    Goodyear CS; Patel A; Barnes E; Willicombe M; Siebert S; de Silva TI; Snowden JA; Lim SH; Bowden SJ; Billingham L; Richter A; Carroll M; Carr EJ; Beale R; Rea D; Parry H; Pirrie S; Lim Z; Satsangi J; Dunachie SJ; Cook G; Miller P; Basu N; Gilmour A; Hodgkins AM; Evans L; Hughes A; Longet S; Meacham G; Yong KL; A'Hearne MJ; Koh MBC; Burns SO; Orchard K; Paterson C; McIlroy G; Murray SM; Thomson T; Dimitriadis S; Goulston L; Miller S; Keillor V; Prendecki M; Thomas D; Kirkham A; McInnes IB; Kearns P;
    Lancet Rheumatol; 2024 Jun; 6(6):e339-e351. PubMed ID: 38734019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity, reactogenicity, and safety of a second booster with BNT162b2 or full-dose mRNA-1273: A randomized VACCELERATE trial in adults aged ≥75 years (EU-COVAT-1-AGED Part B).
    Stemler J; Yeghiazaryan L; Stephan C; Mohn KG; Carcas-Sansuan AJ; Rodriguez ER; Moltó J; Mitxeltorena IV; Welte T; Zablockienė B; Akova M; Bethe U; Heringer S; Salmanton-García J; Jeck J; Tischmann L; Zarrouk M; Cüppers A; Biehl LM; Grothe J; Mellinghoff SC; Nacov JA; Neuhann JM; Sprute R; Frías-Iniesta J; Negi R; Gaillard C; Saini G; León AG; Mallon PWG; Lammens C; Hotterbeekx A; Loens K; Malhotra-Kumar S; Goossens H; Kumar-Singh S; König F; Posch M; Koehler P; Cornely OA;
    Int J Infect Dis; 2024 Sep; 146():107161. PubMed ID: 38992789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
    Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
    Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
    Hillus D; Schwarz T; Tober-Lau P; Vanshylla K; Hastor H; Thibeault C; Jentzsch S; Helbig ET; Lippert LJ; Tscheak P; Schmidt ML; Riege J; Solarek A; von Kalle C; Dang-Heine C; Gruell H; Kopankiewicz P; Suttorp N; Drosten C; Bias H; Seybold J; ; Klein F; Kurth F; Corman VM; Sander LE
    Lancet Respir Med; 2021 Nov; 9(11):1255-1265. PubMed ID: 34391547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
    Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
    Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct T cell responsiveness to different COVID-19 vaccines and cross-reactivity to SARS-CoV-2 variants with age and CMV status.
    Brummelman J; Suárez-Hernández S; de Rond L; Bogaard-van Maurik M; Molenaar P; van Wijlen E; Oomen D; Beckers L; Rots NY; van Beek J; Nicolaie MA; van Els CACM; Boer MC; Kaaijk P; Buisman AM; de Wit J
    Front Immunol; 2024; 15():1392477. PubMed ID: 38774878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
    Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
    Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
    Sablerolles RSG; Rietdijk WJR; Goorhuis A; Postma DF; Visser LG; Geers D; Schmitz KS; Garcia Garrido HM; Koopmans MPG; Dalm VASH; Kootstra NA; Huckriede ALW; Lafeber M; van Baarle D; GeurtsvanKessel CH; de Vries RD; van der Kuy PHM;
    N Engl J Med; 2022 Mar; 386(10):951-963. PubMed ID: 35045226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.
    Garza-Silva A; Rivera-Salinas D; Rivera-Cavazos A; Fernández-Chau IF; Cepeda-Medina AB; Morales-Rodríguez DP; Barco-Flores IA; Sanz-Sánchez MÁ; Acciardi C; Paez-Bo G; Teixeira MM; Azzolini E; Pozzi C; Rescigno M; Romero-Ibarguengoitia ME
    Front Immunol; 2024; 15():1403784. PubMed ID: 38807602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.